•  
  •  
 

Abstract

Introduction. Frailty syndrome, the newest elderly health predictor, associated with higher morbidity and mortality. PPI are often used in elderly due to presence of upper gastrointestinal complaints, and relates with polypharmacy as one of the risk factor for frailty syndrome. There is no study of the relationship between long term PPI use and frailty syndrome in elderly. Methods. A case control study included subjects 60 years and above with good cognitive status. All subjects with history of hypersensitivity of PPI were excluded. Elderly who were frail based on FI-40 item were defined as cases, while individuals that were not frail were classified as control. Primary data (included frailty status) was collected on March-June 2013 by Seto E and Sumantri S, et al. Secondary data used in this current study were gathered from the primary data of previous research and from the medical record taken from geriatric and diabetic outpatient clinics Cipto Mangunkusumo Hospital. Results. There were 225 subjects collected (75 cases: 150 controls), 59,6% were female (mean age 72,14 years old, SD ± 6,4 years) and 47,1% with higher education. Lower education, divorced, poor nutrition, dependent, needed caregiver, economically insufficient, more comorbidity and poor health condition were seen in frail group. The proportion of long term PPI use were 40,9%. Long term PPI medication increased the risk of frailty syndrome (Crude OR 2,154; CI 95% 1,225-3,778; p<0,007) with adjusted OR 1,83 (CI 95% 1,02-3,37) after adjusting with nutrition and smoking variables. Conclusions. Long term use of PPI significantly increase the risk of frailty syndrome compared to the non-users.

References

1. U.S. Department of Health and Human Services. Administration Community Living: Aging Statistics [Internet]. Washington DC: U.S Department of Health and Human Services; April 2014 [cited 21 April 2014]. Available from: http://www.aoa.acl.gov/Aging_ Statistics/index.aspx. 2. Badan Perencanaan Pembangunan Nasional Badan Pusat Statistik United Nations. Population Funds: Proyeksi Penduduk Indonesia 2010-2035. Dalam: BPN/Bappenas K, editor. Indonesia: Badan Pusat Statistik; 2013. 3. Bortz WM, 2nd. A conceptual framework of frailty: a review. J Gerontol A Biol Sci Med Sci. 2002;57(5):M283-8. 4. Moorhouse P, Rockwood K. Frailty and its quantitative clinical evaluation. J R Coll Physicians Edinb. 2012;42(4):333-40. 5. Kulminski A, Yashin A, Arbeev K, Akushevich I, Ukraintseva S, Land K, et al. Cumulative index of health disorders as an indicator of aging-associated processes in the elderly: results from analyses of the National Long Term Care Survey. Mech Ageing Dev. 2007;128(3):250-8. 6. Rockwood K, Hogan DB, MacKnight C. Conceptualisation and measurement of frailty in elderly people. Drugs Aging. 2000;17(4):295-302. 7. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-56. 8. Song X, Mitnitski A, Rockwood K. Prevalence and 10-year outcomes of frailty in older adults in relation to deficit accumulation. J Am Geriatr Soc. 2010;58(4):681-7. 9. Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc. 2012;60(8):1487-92. 10. Seto E. Uji diagnostik sistem skor sindrom frailtyberdasarkan Cardiovascular Health Study, Study of Osteoporotic Fracture dan indeks frailty berbasis Comprehensive Geriatric Assessment dibandingkan dengan indeks frailty 40 item pada pasien usia lanjut [Tesis]. Jakarta: Universitas Indonesia; 2014. 11. Seto E. Uji diagnostik sistem skor sindrom frailtyberdasarkan Cardiovascular Health Study, Study of Osteoporotic Fracture dan indeks frailty berbasis Comprehensive Geriatric Assessment dibandingkan dengan indeks frailty40 item pada pasien usia lanjut [Tesis]. Jakarta: Universitas Indonesia; 2014. 12. Bortz W. Understanding frailty. J Gerontol A Biol Sci Med Sci. 2010;65(3):255-6. 13. Fedarko NS. The biology of aging and frailty. Clin Geriatr Med. 2011;27(1):27-37. 14. Alameel T, Basheikh M, Andrew MK. Digestive symptoms in older adults: prevalence and associations with institutionalization and mortality. Can J Gastroenterol. 2012;26(12):881-4. 15. Talley NJ, Vakil N, Practice Parameters Committee of the American College of G. Guidelines for the management of dyspepsia. Am J Gastroenterol. 2005;100(10):2324-37. 16. Fallone CA. Management of dyspepsia in the elderly. Geriatrics and Aging. 2002;5(10):18-22. 17. Van Zanten SV. Diagnosis and management of gastroesophageal reflux disease and dyspepsia among older adults. Geriatrics and Aging. 2008;11(6):363-67. 18. El-Serag HB, Talley NJ. Systemic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther. 2004;19(6):643-54. 19. Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007;83(975):66-8. 20. Chan FK, Abraham NS, Scheiman JM, Laine L, First International Working Party on G, Cardiovascular Effects of Nonsteroidal Antiinflammatory D, et al. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Antiinflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol. 2008;103(11):2908-18. 21. Corleto VD, Festa S, Di Giulio E, Annibale B. Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes. 2014;21(1):3-8. 22. Katz MH. Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med. 2010;170(9):747-8. 23. Ament PW, Dicola DB, James ME. Reducing adverse effects of proton pump inhibitors. Am Fam Physician. 2012;86(1):66-70. 24. Samsuria SD. Survei Penggunaan Proton Pump Inhibitor di Poliklinik Geriatri Terpadu Rumah Sakit Cipto Mangunkusumo: Sebuah Pilot Study. Jakarta; 2013. 25. Johnson DA, Oldfield ECt. Reported side effects and complications of longterm proton pump inhibitor use: dissecting the evidence. Clin Gastroenterol Hepatol. 2013;11(5):458-64. 26. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther. 2010;31(11):1165-77. 27. Raghunath AS, O'Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther. 2005;22(Suppl 1):55-63. 28. Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils and pitfalls of longterm effects of proton pump inhibitors. Expert Rev Clin Pharmacol. 2013;6(4):443-51. 29. Teramura-Gronblad M, Hosia-Randell H, Muurinen S, Pitkala K. Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents. Scand J Prim Health Care. 2010;28(3):154-9. 30. Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. ScientificWorld Journal. 2001;1:323-36. 31. Bohannon RW. Hand-grip dynamometry provides a valid indication of upper extremity strength impairment in home care patients. J Hand Ther. 1998;11(4):258-60. 32. Rockwood K, Song X, Mitnitski A. Changes in relative fitness and frailty across the adult lifespan: evidence from the Canadian National Population Health Survey. CMAJ. 2011;183(8):E487-94. 33. Santos-Eggimann B, Cuenoud P, Spagnoli J, Junod J. Prevalence of frailty in middle-aged and older community-dwelling Europeans living in 10 countries. J Gerontol A Biol Sci Med Sci. 2009;64(6):675-81. 34. McAdams-DeMarco MA, Law A, Salter ML, Boyarsky B, Gimenez L, Jaar BG, et al. Frailty as a novel predictor of mortality and hospitalization in individuals of all ages undergoing hemodialysis. J Am Geriatr Soc. 2013;61(6):896-901. 35. Rockwood K, Mitnitski A. Frailty defined by deficit accumulation and geriatric medicine defined by frailty. Clin Geriatr Med. 2011;27(1):17-26. 36. Kulmala J, Nykanen I, Hartikainen S. Frailty as a predictor of allcause mortality in older men and women. Geriatr Gerontol Int. 2014;14(4):899-905. 37. Serviddio G, Romano AD, Greco A, Rollo T, Bellanti F, Altomare E, et al.Frailty syndrome is associated with altered circulating redox balance and increased markers of oxidative stress. Int J Immunopathol Pharmacol. 2009;22(3):819-27. 38. Joseph B, Pandit V, Rhee P, Aziz H, Sadoun M, Wynne J, et al. Predicting hospital discharge disposition in geriatric trauma patients: is frailty the answer? J Trauma Acute Care Surg. 2014;76(1):196-200. 39. Matsuzawa Y, Konishi M, Akiyama E, Suzuki H, Nakayama N, Kiyokuni M, et al. Association between gait speed as a measure of frailty and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol. 2013;61(19):1964-72. 40. Heuberger RA. The frailty syndrome: a comprehensive review. J Nutr Gerontol Geriatr. 2011;30(4):315-68. 41. Rolland Y, Czerwinski S, Abellan Van Kan G, Morley JE, Cesari M, Onder G, et al. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging. 2008;12(7):433-50. 42. Hubbard RE, O'Mahony MS, Savva GM, Calver BL, Woodhouse KW. Inflammation and frailty measures in older people. J Cell Mol Med. 2009;13(9B):3103-9. 43. Leng SX, Cappola AR, Andersen RE, Blackman MR, Koenig K, Blair M, et al. Serum levels of insulin-like growth factor-I (IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6, in the geriatric syndrome of frailty. Aging Clin Exp Res. 2004;16(2):153-7. 44. Dayhoff-Brannigan M, Ferrucci L, Sun K, Fried LP, Walston J, Varadhan R, et al. Oxidative protein damage is associated with elevated serum interleukin-6 levels among older moderately to severely disabled women living in the community. J Gerontol A Biol Sci Med Sci. 2008;63(2):179-83. 45. Weiss CO. Frailty and chronic diseases in older adults. Clin Geriatr Med. 2011;27(1):39-52. 46. Leng S, Chaves P, Koenig K, Walston J. Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. J Am Geriatr Soc. 2002;50(7):1268-71. 47. Kanapuru B, Ershler WB. Inflammation, coagulation, and the pathway to frailty. Am J Med. 2009;122(7):605-13.

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.